Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
KisqaliⓇ accelerated growth in Q4 (+58%) behind MONALEESA-2 OS
Sales evolution
USD bn, % cc
Ex-US
US
CEZ
KISQALI K L
Robust body of evidence supports positioning Kisqali
as standard of care (SOC) in 1L postmenopausal BC
+58%
■ Positive OS results in 3 Ph3 trials, including ML-2
285
184
187
102
82
98
Q4 2020
Q4 2021
■ The only CDK 4/6 inhibitor to demonstrate OS benefit in 1L
according to NCCN guidelines
Continued growth acceleration and geographic expansion
US share gains driven by positive impact of ML-2 OS data
■ 88% YoY growth ex-US reflecting strong market share gains and
impact of new data
Geographic expansion with public reimbursement recommendation
in Brazil and regulatory submission in China
aBC advanced breast cancer/eBC - early breast cancer ML-MONALEESA. In phase 3 randomized controlled trials, ribociclib + endocrine therapy has shown overall survival benefit in the first-line setting.
34 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation